1
|
Fisher DAC, Laranjeira ABA, Kong T, Snyder SC, Shim K, Fulbright MC, Oh ST. Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice. Exp Hematol 2023; 128:48-66. [PMID: 37611729 PMCID: PMC11227100 DOI: 10.1016/j.exphem.2023.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 07/25/2023] [Accepted: 08/11/2023] [Indexed: 08/25/2023]
Abstract
Hyperactivation of JAK2 kinase is a unifying feature of human Ph- myeloproliferative neoplasms (MPNs), most commonly due to the JAK2 V617F mutation. Mice harboring a homologous mutation in the Jak2 locus exhibit a phenotype resembling polycythemia vera. NFκB pathway hyperactivation is present in myeloid neoplasms, including MPNs, despite scarcity of mutations in NFκB pathway genes. To determine the impact of NFκB pathway hyperactivation in conjunction with Jak2 V617F, we utilized Ikk2 (Ikk2-CA) mice. Pan-hematopoietic Ikk2-CA alone produced depletion of hematopoietic stem cells and B cells. When combined with the Jak2 V617F mutation, Ikk2-CA rescued the polycythemia vera phenotype of Jak2 V617F. Likewise, Jak2 V617F ameliorated defects in hematopoiesis produced by Ikk2-CA. Single-cell RNA sequencing of hematopoietic stem and progenitor cells revealed multiple genes antagonistically regulated by Jak2 and Ikk2, including subsets whose expression was altered by Jak2 V617F and/or Ikk2-CA but partly or fully rectified in the double mutant. We hypothesize that Jak2 promotes hematopoietic stem cell population self-renewal, whereas Ikk2 promotes myeloid lineage differentiation, and biases cell fates at several branch points in hematopoiesis. Jak2 and Ikk2 both regulate multiple genes affecting myeloid maturation and cell death. Therefore, the presence of dual Jak2 and NFκB hyperactivation may present neomorphic therapeutic vulnerabilities in myeloid neoplasms.
Collapse
Affiliation(s)
- Daniel A C Fisher
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
| | - Angelo B A Laranjeira
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
| | - Tim Kong
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
| | - Steven C Snyder
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
| | - Kevin Shim
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
| | - Mary C Fulbright
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
| | - Stephen T Oh
- Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO.
| |
Collapse
|
2
|
Buks R, Dagher T, Rotordam MG, Monedero Alonso D, Cochet S, Gautier EF, Chafey P, Cassinat B, Kiladjian JJ, Becker N, Plo I, Egée S, El Nemer W. Altered Ca 2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells 2021; 11:49. [PMID: 35011611 PMCID: PMC8750512 DOI: 10.3390/cells11010049] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 02/07/2023] Open
Abstract
Over 95% of Polycythemia Vera (PV) patients carry the V617F mutation in the tyrosine kinase Janus kinase 2 (JAK2), resulting in uncontrolled erythroid proliferation and a high risk of thrombosis. Using mass spectrometry, we analyzed the RBC membrane proteome and showed elevated levels of multiple Ca2+ binding proteins as well as endoplasmic-reticulum-residing proteins in PV RBC membranes compared with RBC membranes from healthy individuals. In this study, we investigated the impact of JAK2V617F on (1) calcium homeostasis and RBC ion channel activity and (2) protein expression and sorting during terminal erythroid differentiation. Our data from automated patch-clamp show modified calcium homeostasis in PV RBCs and cell lines expressing JAK2V617F, with a functional impact on the activity of the Gárdos channel that could contribute to cellular dehydration. We show that JAK2V617F could play a role in organelle retention during the enucleation step of erythroid differentiation, resulting in modified whole cell proteome in reticulocytes and RBCs in PV patients. Given the central role that calcium plays in the regulation of signaling pathways, our study opens new perspectives to exploring the relationship between JAK2V617F, calcium homeostasis, and cellular abnormalities in myeloproliferative neoplasms, including cellular interactions in the bloodstream in relation to thrombotic events.
Collapse
Affiliation(s)
- Ralfs Buks
- BIGR, UMR_S1134, Inserm, Université de Paris, F-75015 Paris, France; (R.B.); (S.C.)
- Institut National de la Transfusion Sanguine, F-75015 Paris, France
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
| | - Tracy Dagher
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- U1287, Inserm, Université Paris-Saclay, Gustave Roussy, F-94800 Villejuif, France
| | - Maria Giustina Rotordam
- Nanion Technologies GmbH, 80339 Munich, Germany; (M.G.R.); (N.B.)
- Theoretical Medicine and Biosciences, Medical Faculty, Saarland University, Kirrbergerstr. 100, DE-66424 Homburg, Germany
| | - David Monedero Alonso
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Sorbonne Université, CNRS, UMR LBI2M, Station Biologique de Roscoff SBR, F-29680 Roscoff, France
| | - Sylvie Cochet
- BIGR, UMR_S1134, Inserm, Université de Paris, F-75015 Paris, France; (R.B.); (S.C.)
- Institut National de la Transfusion Sanguine, F-75015 Paris, France
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
| | - Emilie-Fleur Gautier
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Institut Imagine-INSERM U1163, Necker Hospital, Université de Paris, F-75015 Paris, France
- Proteomics Platform 3P5, Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104 Paris, France;
| | - Philippe Chafey
- Proteomics Platform 3P5, Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104 Paris, France;
| | - Bruno Cassinat
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- IRSL, U1131, INSERM, Université de Paris, F-75010 Paris, France
- Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, AP-HP, F-75010 Paris, France
| | - Jean-Jacques Kiladjian
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- IRSL, U1131, INSERM, Université de Paris, F-75010 Paris, France
- Centre d’Investigations Cliniques, Hôpital Saint-Louis, Université de Paris, F-75010 Paris, France
| | - Nadine Becker
- Nanion Technologies GmbH, 80339 Munich, Germany; (M.G.R.); (N.B.)
| | - Isabelle Plo
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- U1287, Inserm, Université Paris-Saclay, Gustave Roussy, F-94800 Villejuif, France
| | - Stéphane Egée
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Sorbonne Université, CNRS, UMR LBI2M, Station Biologique de Roscoff SBR, F-29680 Roscoff, France
| | - Wassim El Nemer
- BIGR, UMR_S1134, Inserm, Université de Paris, F-75015 Paris, France; (R.B.); (S.C.)
- Institut National de la Transfusion Sanguine, F-75015 Paris, France
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Etablissement Français du Sang PACA-Corse, F-13005Marseille, France
- Aix Marseille Univ, EFS, CNRS, ADES, “Biologie des Groupes Sanguins”, F-13005 Marseille, France
| |
Collapse
|
3
|
Nakagawa MM, Rathinam CV. Constitutive Activation of the Canonical NF-κB Pathway Leads to Bone Marrow Failure and Induction of Erythroid Signature in Hematopoietic Stem Cells. Cell Rep 2019; 25:2094-2109.e4. [PMID: 30463008 PMCID: PMC6945759 DOI: 10.1016/j.celrep.2018.10.071] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 08/29/2018] [Accepted: 10/19/2018] [Indexed: 11/24/2022] Open
Abstract
Constitutive activation of the canonical NF-κB pathway has been associated with a variety of human pathologies. However, molecular mechanisms through which canonical NF-κB affects hematopoiesis remain elusive. Here, we demonstrate that deregulated canonical NF-κB signals in hematopoietic stem cells (HSCs) cause a complete depletion of HSC pool, pancytopenia, bone marrow failure, and premature death. Constitutive activation of IKK2 in HSCs leads to impaired quiescence and loss of function. Gene set enrichment analysis (GSEA) identified an induction of “erythroid signature” in HSCs with augmented NF-κB activity. Mechanistic studies indicated a reduction of thrombopoietin (TPO)-mediated signals and its downstream target p57 in HSCs, due to reduced c-MpI expression in a cell-intrinsic manner. Molecular studies established Klf1 as a key suppressor of c-MpI in HSPCs with increased NF-κB. In essence, these studies identified a previously unknown mechanism through which exaggerated canonical NF-κB signals affect HSCs and cause pathophysiology. Nakagawa and Rathinam demonstrate that constitutive activation of IKK2 in HSCs causes a complete depletion of the HSC pool and impairs HSC functions due to a loss of “sternness” signature and an induction of erythroid signature.
Collapse
Affiliation(s)
- Masahiro Marshall Nakagawa
- Department of Genetics and Development, Columbia University Medical Center, 701 W. 168(th) Street, New York, NY 10032, USA
| | - Chozha Vendan Rathinam
- Department of Genetics and Development, Columbia University Medical Center, 701 W. 168(th) Street, New York, NY 10032, USA; Institute of Human Virology, University of Maryland, Baltimore, MD, USA; Center for Stem Cell & Regenerative Medicine, University of Maryland, Baltimore, MD, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 725 W. Lombard Street, Baltimore, MD 21201, USA.
| |
Collapse
|
4
|
Zriwil A, Böiers C, Kristiansen TA, Wittmann L, Yuan J, Nerlov C, Sitnicka E, Jacobsen SEW. Direct role of FLT3 in regulation of early lymphoid progenitors. Br J Haematol 2018; 183:588-600. [PMID: 30596405 PMCID: PMC6492191 DOI: 10.1111/bjh.15578] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 06/21/2018] [Indexed: 02/01/2023]
Abstract
Given that FLT3 expression is highly restricted on lymphoid progenitors, it is possible that the established role of FLT3 in the regulation of B and T lymphopoiesis reflects its high expression and role in regulation of lymphoid-primed multipotent progenitors (LMPPs) or common lymphoid progenitors (CLPs). We generated a Flt3 conditional knock-out (Flt3fl/fl) mouse model to address the direct role of FLT3 in regulation of lymphoid-restricted progenitors, subsequent to turning on Rag1 expression, as well as potentially ontogeny-specific roles in B and T lymphopoiesis. Our studies establish a prominent and direct role of FLT3, independently of the established role of FLT3 in regulation of LMPPs and CLPs, in regulation of fetal as well as adult early B cell progenitors, and the early thymic progenitors (ETPs) in adult mice but not in the fetus. Our findings highlight the potential benefit of targeting poor prognosis acute B-cell progenitor leukaemia and ETP leukaemia with recurrent FLT3 mutations using clinical FLT3 inhibitors.
Collapse
Affiliation(s)
- Alya Zriwil
- Lund Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden.,Division of Molecular Haematology, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Charlotta Böiers
- Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
| | - Trine A Kristiansen
- Division of Molecular Haematology, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Lilian Wittmann
- Lund Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden.,Division of Molecular Haematology, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Joan Yuan
- Division of Molecular Haematology, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Claus Nerlov
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
| | - Ewa Sitnicka
- Lund Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden.,Division of Molecular Haematology, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Sten E W Jacobsen
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.,Wallenberg Institute for Regenerative Medicine, Department of Cell and Molecular Biology, Center for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden
| |
Collapse
|
5
|
Schito L, Rey S, Konopleva M. Integration of hypoxic HIF-α signaling in blood cancers. Oncogene 2017; 36:5331-5340. [DOI: 10.1038/onc.2017.119] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 01/16/2017] [Accepted: 02/26/2017] [Indexed: 12/15/2022]
|
6
|
Perez-Cunningham J, Boyer SW, Landon M, Forsberg EC. Hematopoietic stem cell-specific GFP-expressing transgenic mice generated by genetic excision of a pan-hematopoietic reporter gene. Exp Hematol 2016; 44:755-764.e1. [PMID: 27185381 DOI: 10.1016/j.exphem.2016.05.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Revised: 04/11/2016] [Accepted: 05/03/2016] [Indexed: 11/24/2022]
Abstract
Selective labeling of specific cell types by expression of green fluorescent protein (GFP) within the hematopoietic system would have great utility in identifying, localizing, and tracking different cell populations in flow cytometry, microscopy, lineage tracing, and transplantation assays. In this report, we describe the generation and characterization of a new transgenic mouse line with specific GFP labeling of all nucleated hematopoietic cells and platelets. This new "Vav-GFP" mouse line labels the vast majority of hematopoietic cells with GFP during both embryonic development and adulthood, with particularly high expression in hematopoietic stem and progenitor cells (HSPCs). With the exception of transient labeling of fetal endothelial cells, GFP expression is highly selective for hematopoietic cells and persists in donor-derived progeny after transplantation of HSPCs. Finally, we also demonstrate that the loxP-flanked reporter allows for specific GFP labeling of different hematopoietic cell subsets when crossed to various Cre reporter lines. By crossing Vav-GFP mice to Flk2-Cre mice, we obtained robust and highly selective GFP expression in hematopoietic stem cells (HSCs). These data describe a new mouse model capable of directing GFP labeling exclusively of hematopoietic cells or exclusively of HSCs.
Collapse
Affiliation(s)
- Jessica Perez-Cunningham
- Department of Biomolecular Engineering, Institute for the Biology of Stem Cells, University of California, Santa Cruz, CA
| | - Scott W Boyer
- Department of Biomolecular Engineering, Institute for the Biology of Stem Cells, University of California, Santa Cruz, CA
| | - Mark Landon
- Department of Biomolecular Engineering, Institute for the Biology of Stem Cells, University of California, Santa Cruz, CA
| | - E Camilla Forsberg
- Department of Biomolecular Engineering, Institute for the Biology of Stem Cells, University of California, Santa Cruz, CA.
| |
Collapse
|
7
|
Leon-Rico D, Aldea M, Sanchez R, Segovia JC, Weiss LA, Hidalgo A, Bueren JA, Almarza E. Brief report: reduced expression of CD18 leads to the in vivo expansion of hematopoietic stem cells in mouse bone marrow. Stem Cells 2015; 32:2794-8. [PMID: 24906078 DOI: 10.1002/stem.1762] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Revised: 05/05/2014] [Accepted: 05/15/2014] [Indexed: 01/12/2023]
Abstract
Leukocyte adhesion deficiency type-I is a primary immunodeficiency caused by mutations in the ITGB2 gene (CD18 leukocyte integrin) which lead to defects in leukocyte extravasation. To investigate the role of CD18 in hematopoietic stem cell (HSC) biology, we have thoroughly characterized the HSCs of CD18 Itgb2(tm1bay) hypomorphic mice (CD18(HYP) ) both by flow cytometry and using in vitro and in vivo transplantation assays. Flow cytometry analyses and cultures in methyl cellulose revealed that bone marrow (BM) from CD18(HYP) mice was enriched in hematopoietic precursors, mainly early quiescent short-term and long-term Hematopoietic progenitors cells. Strikingly, BM competition assays showed a progressive expansion of CD18(HYP) -derived hematopoiesis in recipient mice. Additionally, we provide evidence that this HSC expansion was not caused by an increased homing capacity of CD18(HYP) HSCs or by alterations in the hematopoietic environment of CD18(HYP) mice due to defects in neutrophils clearance. On the contrary, our data demonstrated that the reduced expression of CD18 causes a cell-autonomous expansion in the HSC compartment, thus revealing unexpected regulatory functions for CD18 in mouse HSCs.
Collapse
Affiliation(s)
- Diego Leon-Rico
- Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Sapin; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Leon-Rico D, Fernández-García M, Aldea M, Sánchez R, Peces-Barba M, Martinez-Palacio J, Yáñez RM, Almarza E. Comparison of haematopoietic stem cell engraftment through the retro-orbital venous sinus and the lateral vein: alternative routes for bone marrow transplantation in mice. Lab Anim 2015; 49:132-41. [PMID: 25586937 DOI: 10.1177/0023677214567915] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Bone marrow transplantation in mice is performed by intravenous administration of haematopoietic repopulating cells, usually via the lateral tail vein. This technique can be technically challenging to carry out and may cause distress to the mice. The retro-orbital sinus is a large area where there is a confluence of several vessels that provides an alternative route for intravenous access. Retro-orbital injection, although aesthetically unpleasant, can be performed rapidly without requiring mechanical restriction or heat-induced vasodilation. In addition, this technique can be easily learned by novice manipulators. This route of administration has been reported for use in bone marrow transplantation but there is no comparison of retro-orbital and tail vein injections reported for this specific purpose, although both routes have been compared for many other applications. Here, we provide for the first time a comprehensive comparison between tail vein and retro-orbital injections for two different bone marrow transplant scenarios in P3B and B6D2F1 mice. In both cases, no significant differences regarding donor engraftment were observed between mice transplanted using each of the techniques. Haematological counts and leukocyte subpopulation distribution were practically identical between both animal groups. Moreover, donor engraftment levels were less homogenous when cells were transplanted by tail vein injection, probably due to a higher risk of failure associated with this technique. All these data suggest that retro-orbital injection is a compelling alternative to conventional tail vein injection for bone marrow transplant in mice, providing similar and more homogenous haematopoietic reconstitution.
Collapse
Affiliation(s)
- D Leon-Rico
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain Instituto de Investigación Sanitaria Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain
| | - M Fernández-García
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain Instituto de Investigación Sanitaria Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain
| | - M Aldea
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain Instituto de Investigación Sanitaria Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain
| | - R Sánchez
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain Instituto de Investigación Sanitaria Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain
| | - M Peces-Barba
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain
| | - J Martinez-Palacio
- Animal Facility, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R M Yáñez
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain Instituto de Investigación Sanitaria Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain
| | - E Almarza
- Division of Haematopoietic Innovative Therapies. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain Instituto de Investigación Sanitaria Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain
| |
Collapse
|
9
|
Abstract
Ionizing radiation exposure is fatal due to widespread hematopoietic destruction. Lento et al. found that TCF/Lef H2B-GFP reporter mice display robust activation in HSCs following injury. Loss of β-catenin impaired HSC regeneration and recovery after radiation damage. β-Catenin-null HSCs exhibited reduced expression of catalase, an enzyme responsible for eliminating hydrogen peroxide. Consistent with this, irradiated β-catenin-null HSCs accumulate ROS and double-strand breaks. This study suggests that β-catenin loss compromises genomic integrity after ionizing radiation injury. Accidental or deliberate ionizing radiation exposure can be fatal due to widespread hematopoietic destruction. However, little is known about either the course of injury or the molecular pathways that regulate the subsequent regenerative response. Here we show that the Wnt signaling pathway is critically important for regeneration after radiation-induced injury. Using Wnt reporter mice, we show that radiation triggers activation of Wnt signaling in hematopoietic stem and progenitor cells. β-Catenin-deficient mice, which lack the ability to activate canonical Wnt signaling, exhibited impaired hematopoietic stem cell regeneration and bone marrow recovery after radiation. We found that, as part of the mechanism, hematopoietic stem cells lacking β-catenin fail to suppress the generation of reactive oxygen species and cannot resolve DNA double-strand breaks after radiation. Consistent with the impaired response to radiation, β-catenin-deficient mice are also unable to recover effectively after chemotherapy. Collectively, these data indicate that regenerative responses to distinct hematopoietic injuries share a genetic dependence on β-catenin and raise the possibility that modulation of Wnt signaling may be a path to improving bone marrow recovery after damage.
Collapse
|
10
|
Zimdahl B, Ito T, Blevins A, Bajaj J, Konuma T, Weeks J, Koechlein CS, Kwon HY, Arami O, Rizzieri D, Broome HE, Chuah C, Oehler VG, Sasik R, Hardiman G, Reya T. Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. Nat Genet 2014; 46:245-52. [PMID: 24487275 PMCID: PMC4267534 DOI: 10.1038/ng.2889] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 01/09/2014] [Indexed: 01/08/2023]
Abstract
Cell fate can be controlled through asymmetric division and segregation of protein determinants, but the regulation of this process in the hematopoietic system is poorly understood. Here we show that the dynein-binding protein Lis1 is critically required for hematopoietic stem cell function and leukemogenesis. Conditional deletion of Lis1 (also known as Pafah1b1) in the hematopoietic system led to a severe bloodless phenotype, depletion of the stem cell pool and embryonic lethality. Further, real-time imaging revealed that loss of Lis1 caused defects in spindle positioning and inheritance of cell fate determinants, triggering accelerated differentiation. Finally, deletion of Lis1 blocked the propagation of myeloid leukemia and led to a marked improvement in survival, suggesting that Lis1 is also required for oncogenic growth. These data identify a key role for Lis1 in hematopoietic stem cells and mark its directed control of asymmetric division as a critical regulator of normal and malignant hematopoietic development.
Collapse
Affiliation(s)
- Bryan Zimdahl
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710
| | - Takahiro Ito
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Allen Blevins
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Jeevisha Bajaj
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Takaaki Konuma
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Joi Weeks
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Claire S. Koechlein
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Hyog Young Kwon
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - Omead Arami
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
| | - David Rizzieri
- Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710
| | - H. Elizabeth Broome
- Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA, 92093
| | - Charles Chuah
- Department of Haematology, Singapore General Hospital, Singapore
| | - Vivian G. Oehler
- Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109
| | - Roman Sasik
- Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, 92093
| | - Gary Hardiman
- Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, 92093
| | - Tannishtha Reya
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, 92093
- Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92093
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710
- Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA, 92093
| |
Collapse
|
11
|
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood 2013; 122:1464-77. [PMID: 23863895 DOI: 10.1182/blood-2013-04-498956] [Citation(s) in RCA: 117] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
The acquired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involved in BCR/ABL-negative myeloproliferative neoplasms (MPNs), but its effect on hematopoietic stem cells as a driver of disease emergence has been questioned. Therefore, we reinvestigated the role of endogenous expression of JAK2(V617F) on early steps of hematopoiesis as well as the effect of interferon-α (IFNα), which may target the JAK2(V617F) clone in humans by using knock-in mice with conditional expression of JAK2(V617F) in hematopoietic cells. These mice develop a MPN mimicking polycythemia vera with large amplification of myeloid mature and precursor cells, displaying erythroid endogenous growth and progressing to myelofibrosis. Interestingly, early hematopoietic compartments [Lin-, LSK, and SLAM (LSK/CD48-/CD150+)] increased with the age. Competitive repopulation assays demonstrated disease appearance and progressive overgrowth of myeloid, Lin-, LSK, and SLAM cells, but not lymphocytes, from a low number of engrafted JAK2(V617F) SLAM cells. Finally, IFNα treatment prevented disease development by specifically inhibiting JAK2(V617F) cells at an early stage of differentiation and eradicating disease-initiating cells. This study shows that JAK2(V617F) in mice amplifies not only late but also early hematopoietic cells, giving them a proliferative advantage through high cell cycling and low apoptosis that may sustain MPN emergence but is lost upon IFNα treatment.
Collapse
|
12
|
Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood 2013; 121:5015-24. [PMID: 23670180 DOI: 10.1182/blood-2013-02-486142] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Hematopoiesis is a tightly regulated process resulting in the production of blood cells. Self-renewal and differentiation of hematopoietic stem cells (HSCs) are key processes in hematopoietic development. Disruption of these steps can lead to altered cell distribution and disease. To investigate the role of the nuclear factor-κB subunit RelA/p65 in the regulation of HSCs in vivo, we generated mice lacking RelA/p65 in the hematopoietic compartment. Using this model system, we show that loss of p65 severely impairs HSC function and occurs in conjunction with increased hematopoietic stem and progenitor cell cycling, extramedullary hematopoiesis, and differentiation defects. Gene array studies of phenotypic HSCs indicate the up-regulation of genes normally expressed in lineage restricted cells, as well as the down-regulation of genes involved in HSC maintenance and homeostasis. We hypothesize that changes in gene expression in p65-deficient cells lead to decreased self-renewal and differentiation efficiency of hematopoietic stem and progenitor cells. These studies demonstrate that p65 is an important regulator of hematopoiesis through the transcription of genes involved in HSC fate.
Collapse
|
13
|
HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency. Blood 2012; 119:2789-98. [PMID: 22308296 DOI: 10.1182/blood-2011-10-387902] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Cited2 is a transcriptional modulator involved in various biologic processes including fetal liver hematopoiesis. In the present study, the function of Cited2 in adult hematopoiesis was investigated in conditional knockout mice. Deletion of Cited2 using Mx1-Cre resulted in increased hematopoietic stem cell (HSC) apoptosis, loss of quiescence, and increased cycling, leading to a severely impaired reconstitution capacity as assessed by 5-fluorouracil treatment and long-term transplantation. Transcriptional profiling revealed that multiple HSC quiescence- and hypoxia-related genes such as Egr1, p57, and Hes1 were affected in Cited2-deficient HSCs. Because Cited2 is a negative regulator of HIF-1, which is essential for maintaining HSC quiescence, and because we demonstrated previously that decreased HIF-1α gene dosage partially rescues both cardiac and lens defects caused by Cited2 deficiency, we generated Cited2 and HIF-1α double-knockout mice. Additional deletion of HIF-1α in Cited2-knockout BM partially rescued impaired HSC quiescence and reconstitution capacity. At the transcriptional level, deletion of HIF-1α restored expression of p57 and Hes1 but not Egr1 to normal levels. Our results suggest that Cited2 regulates HSC quiescence through both HIF-1-dependent and HIF-1-independent pathways.
Collapse
|
14
|
Abstract
Hypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1α has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1α results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1α(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1α pathway. Together, these results demonstrate that HIF1α represents a critical pathway in LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating LSCs in CML.
Collapse
|
15
|
Ilan L, Katzav S. Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation. PLoS One 2012; 7:e29939. [PMID: 22253833 PMCID: PMC3256210 DOI: 10.1371/journal.pone.0029939] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Accepted: 12/07/2011] [Indexed: 01/09/2023] Open
Abstract
Vav1 is a signal transducer protein that functions as a guanine nucleotide exchange factor for the Rho/Rac GTPases in the hematopoietic system where it is exclusively expressed. Recently, Vav1 was shown to be involved in several human malignancies including neuroblastoma, lung cancer, and pancreatic ductal adenocarcinoma (PDA). Although some factors that affect vav1 expression are known, neither the physiological nor pathological regulation of vav1 expression is completely understood. We demonstrate herein that mutations in putative transcription factor binding sites at the vav1 promoter affect its transcription in cells of different histological origin. Among these sites is a consensus site for c-Myb, a hematopoietic-specific transcription factor that is also found in Vav1-expressing lung cancer cell lines. Depletion of c-Myb using siRNA led to a dramatic reduction in vav1 expression in these cells. Consistent with this, co-transfection of c-Myb activated transcription of a vav1 promoter-luciferase reporter gene construct in lung cancer cells devoid of Vav1 expression. Together, these results indicate that c-Myb is involved in vav1 expression in lung cancer cells. We also explored the methylation status of the vav1 promoter. Bisulfite sequencing revealed that the vav1 promoter was completely unmethylated in human lymphocytes, but methylated to various degrees in tissues that do not normally express vav1. The vav1 promoter does not contain CpG islands in proximity to the transcription start site; however, we demonstrated that methylation of a CpG dinucleotide at a consensus Sp1 binding site in the vav1 promoter interferes with protein binding in vitro. Our data identify two regulatory mechanisms for vav1 expression: binding of c-Myb and CpG methylation of 5′ regulatory sequences. Mutation of other putative transcription factor binding sites suggests that additional factors regulate vav1 expression as well.
Collapse
Affiliation(s)
- Lena Ilan
- Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, Jerusalem, Israel
| | - Shulamit Katzav
- Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, Jerusalem, Israel
- * E-mail:
| |
Collapse
|
16
|
Abstract
The Hedgehog signaling pathway is highly conserved and plays an essential role in the embryonic development of a wide variety of organs. In adult tissues, such as the central nervous system, it may also be required for homeostasis and repair following injury. The role of Hedgehog signaling in regulating hematopoiesis is not entirely clear. Evidence has shown that Hedgehog signaling is required for both primitive hematopoiesis in the developing embryo, as well as for definitive hematopoiesis in the adult. However, several studies also suggest that Hedgehog pathway activity is completely dispensable in postnatal hematopoiesis. In this review, we discuss the current understanding of Hedgehog signaling in vertebrate hematopoiesis, as well as the contradictory findings that have been reported.
Collapse
Affiliation(s)
- Yiting Lim
- The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
| | | |
Collapse
|
17
|
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2007; 111:3931-40. [PMID: 18160670 DOI: 10.1182/blood-2007-08-107748] [Citation(s) in RCA: 336] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild-type Jak2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild-type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis, and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild-type JAK2 is critical for the phenotypic manifestation. A similar correlation was also found in patients with MPD.
Collapse
|
18
|
Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12:528-41. [PMID: 18068630 PMCID: PMC2262869 DOI: 10.1016/j.ccr.2007.11.003] [Citation(s) in RCA: 455] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2006] [Revised: 06/15/2007] [Accepted: 11/02/2007] [Indexed: 12/16/2022]
Abstract
A key characteristic of stem cells and cancer cells is their ability to self-renew. To test if Wnt signaling can regulate the self-renewal of both stem cells and cancer cells in the hematopoietic system, we developed mice that lack beta-catenin in their hematopoietic cells. Here we show that beta-catenin-deficient mice can form HSCs, but that these cells are deficient in long-term growth and maintenance. Moreover, beta-catenin deletion causes a profound reduction in the ability of mice to develop BCR-ABL-induced chronic myelogenous leukemia (CML), while allowing progression of acute lymphocytic leukemia (ALL). These studies demonstrate that Wnt signaling is required for the self-renewal of normal and neoplastic stem cells in the hematopoietic system.
Collapse
Affiliation(s)
- Chen Zhao
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
| | - Jordan Blum
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
| | - Alan Chen
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
| | - Hyog Young Kwon
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
| | - Seung Hye Jung
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
| | - J. Michael Cook
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
| | - Anand Lagoo
- Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
| | - Tannishtha Reya
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
- *Correspondence:
| |
Collapse
|
19
|
Kim WI, Wiesner SM, Largaespada DA. Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells. Exp Hematol 2007; 35:1231-9. [PMID: 17560009 DOI: 10.1016/j.exphem.2007.04.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2007] [Revised: 04/10/2007] [Accepted: 04/20/2007] [Indexed: 11/24/2022]
Abstract
OBJECTIVE We previously showed that Vav promoter-tetracycline transactivator (Vav-tTA)-driven tetracycline-regulated element (TRE)-NRAS(V12) expression resulted in mastocytosis development in mice. To investigate which hematopoietic cells express TRE-driven transgenes when combined with Vav-tTA, we assayed hematopoietic cells, including bone marrow-derived mast cells (BMMC) and CD34-positive hematopoietic progenitor cells (HPC) as well as myeloid and lymphoid lineages. To determine if suppression of NRAS(V12) expression early in life would delay mastocytosis we treated developing and juvenile mice with doxycycline (Dox). MATERIALS AND METHODS Vav-tTA-driven luciferase expression was assayed by live mouse imaging and relative light unit measurement before or after treating Vav-tTA and TRE-luciferase (TRE-Luc) cotransgenic mice with Dox. Magnetic cell sorting and fluorescence-activating cell sorting methods were used to sort hematopoietic cells. To suppress TRE-mediated luciferase or NRAS(V12) expression in Vav-tTA cotransgenic mice, we added Dox to the drinking water. RESULTS B cells in the bone marrow and T cells in the thymus expressed Vav-tTA-driven luciferase at much higher levels than in myeloid cells, BMMC, and CD34-positive HPC, which showed relatively low levels. Dox treatment completely eliminated the luciferase expression from all hematopoietic cells. Repression of TRE-NRAS(V12) expression early in life was sufficient to increase the latency of mastocytosis development. CONCLUSION The Vav-tTA transgenic line will be very useful for conditional transgene expression in developing B and T cells. Vav-tTA-driven NRAS(V12) expression is sufficient for mastocytosis development, but not for myeloid leukemia. Lymphoid cells are resistant to NRAS(V12) transformation despite high level of expression.
Collapse
Affiliation(s)
- Won-Il Kim
- Graduate Program in Molecular, Cellular, Developmental Biology and Genetics, University of Minnesota, Minneapolis, MN 55455, USA
| | | | | |
Collapse
|
20
|
Almarza E, Río P, Meza NW, Aldea M, Agirre X, Guenechea G, Segovia JC, Bueren JA. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy. Mol Ther 2007; 15:1487-94. [PMID: 17534266 DOI: 10.1038/sj.mt.6300213] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Recent published data have shown the efficacy of gene therapy treatments of certain monogenic diseases. Risks of insertional oncogenesis, however, indicate the necessity of developing new vectors with weaker or cell-restricted promoters to minimize the trans-activation activity of integrated proviruses. We have inserted the proximal promoter of the vav proto-oncogene into self-inactivating lentiviral vectors (vav-LVs) and investigated the expression pattern and therapeutic efficacy of these vectors. Compared with other LVs frequently used in gene therapy, vav-LVs mediated a weak, though homogeneous and stable, expression in in vitro-cultured cells. Transplantation experiments using transduced mouse bone marrow and human CD34(+) cells confirmed the stable activity of the promoter in vivo. To investigate whether the weak activity of this promoter was compatible with a therapeutic effect, a LV expressing the Fanconi anemia A (FANCA) gene was constructed (vav-FANCA LV). Although this vector induced a low expression of FANCA, compared to the expression induced by a LV harboring the spleen focus-forming virus (SFFV) promoter, the two vectors corrected the phenotype of cells from a patient with FA-A with the same efficacy. We propose that self-inactivating vectors harboring weak promoters, such as the vav promoter, will improve the safety of gene therapy and will be of particular interest for the treatment of diseases where a high expression of the transgene is not required.
Collapse
Affiliation(s)
- Elena Almarza
- Hematopoiesis and Gene Therapy Division, CIEMAT/CIBER-ER and Marcelino Botín Foundation, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Among more than 120 genes that are now known to regulate mammalian pigmentation, one of the key genes is MC1R, which encodes the melanocortin 1 receptor, a seven transmembrane G protein-coupled receptor expressed on the surface of melanocytes. Since the monoexonic sequence of the gene was cloned and characterized more than a decade ago, tremendous efforts have been dedicated to the extensive genotyping of mostly red-haired populations all around the world, thus providing allelic variants that may or may not account for melanoma susceptibility in the presence or absence of ultraviolet (UV) exposure. Soluble factors, such as proopiomelanocortin (POMC) derivatives, agouti signal protein (ASP) and others, regulate MC1R expression, leading to improved photoprotection via increased eumelanin synthesis or in contrast, inducing the switch to pheomelanin. However, there is an obvious lack of knowledge regarding the numerous and complex regulatory mechanisms that govern the expression of MC1R at the intra-cellular level, from gene transcription in response to an external stimulus to the expression of the mature receptor on the melanocyte surface.
Collapse
Affiliation(s)
- Francois Rouzaud
- Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Building 37, Room 2132, Bethesda, MD 20892, USA
| | | |
Collapse
|
22
|
Stadtfeld M, Graf T. Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. Development 2004; 132:203-13. [PMID: 15576407 DOI: 10.1242/dev.01558] [Citation(s) in RCA: 181] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Hematopoietic cells have been reported to convert into a number of non-hematopoietic cells types after transplantation/injury. Here, we have used a lineage tracing approach to determine whether hematopoietic plasticity is relevant for the normal development of hepatocytes and endothelial cells, both of which develop in close association with blood cells. Two mouse models were analyzed: vav ancestry mice, in which essentially all hematopoietic cells, including stem cells, irreversibly express yellow fluorescent protein (YFP); and lysozyme ancestry mice, in which all macrophages, as well as a small subset of all other non-myeloid hematopoietic cells, are labeled. Both lines were found to contain YFP+ hepatocytes at similar frequencies, indicating that macrophage to hepatocyte contributions occur in unperturbed mice. However, the YFP+ hepatocytes never formed clusters larger than three cells, suggesting a postnatal origin. In addition, the frequency of these cells was very low (approximately 1 in 75,000) and only increased two- to threefold after acute liver injury. Analysis of the two mouse models revealed no evidence for a hematopoietic origin of endothelial cells, showing that definitive HSCs do not function as hemangioblasts during normal development. Using endothelial cells and hepatocytes as paradigms, our study indicates that hematopoietic cells are tightly restricted in their differentiation potential during mouse embryo development and that hematopoietic plasticity plays at best a minor role in adult organ maintenance and regeneration.
Collapse
Affiliation(s)
- Matthias Stadtfeld
- Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
| | | |
Collapse
|